Affiliation:
1. Department of Pharmacology, Ghent University, Ghent, Belgium
Abstract
Abstract
Objectives
Over the past few years, the use of metallocomplexes for medical purposes has considerably grown. Because of its favourable characteristics, ruthenium has taken a significant place in this expanding field of research. Several ruthenium-containing metal compounds have been developed as delivery agents of physiological important molecules such as nitric oxide (NO) and carbon monoxide (CO).
Key findings
This review focuses on the (vaso)relaxant capacity of ruthenium-based NO-donating and CO-donating molecules in view of their potential usefulness in the treatment of cardiovascular diseases and erectile dysfunction.
Summary
Ruthenium seems to be a valuable candidate for the design of NO-donating and CO-donating molecules. To date, ruthenium remains of interest in drug research as the search for new alternatives is still necessary.
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference98 articles.
1. Medicinal inorganic chemistry: introduction;Orvig;Chem Rev,1999
2. Metal-compounds in therapy and diagnosis;Abrams;Science,1993
3. Ruthenium in medicine: current clinical uses and future prospects;Allardyce;Platin Met Rev,2001
4. Metal based drugs: from serendipity to design;Fricker;Dalton Trans,2007
5. Novel metals and metal complexes as platforms for cancer therapy;Frezza;Curr Pharm Des,2010
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献